GSK Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 5/6

GSK yıllık ortalama 0.3% oranında kazançlarını artırırken, Pharmaceuticals sektöründe kazançlar growing at 12.2% annual. Gelirler growing yılda ortalama 4.4% oranında artmaktadır. GSK'in özkaynak karlılığı 39.4% ve net marjı 17.5%'dir.

Anahtar bilgiler

0.25%

Kazanç büyüme oranı

-0.23%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	5.95%
Gelir büyüme oranı	4.39%
Özkaynak getirisi	39.41%
Net Marj	17.50%
Son Kazanç Güncellemesi	31 Dec 2025

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

GSK nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

OTCPK:GLAX.F Gelir, gider ve kazançlar (GBP Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
31 Dec 25	32,667	5,716	9,013	6,654
30 Sep 25	32,166	5,494	8,968	6,352
30 Jun 25	31,631	3,423	10,573	6,218
31 Mar 25	31,529	3,153	10,831	6,102
31 Dec 24	31,376	2,575	10,847	6,078
30 Sep 24	31,311	2,511	10,821	6,041
30 Jun 24	31,446	4,033	9,266	6,048
31 Mar 24	30,740	4,484	9,143	5,955
31 Dec 23	30,328	4,928	9,156	5,823
30 Sep 23	29,652	6,078	8,965	5,580
30 Jun 23	29,334	5,373	8,767	5,436
31 Mar 23	29,085	4,455	8,460	5,282
31 Dec 22	29,324	4,461	8,179	5,153
30 Sep 22	29,024	3,387	7,803	4,905
30 Jun 22	27,822	3,505	7,429	4,741
31 Mar 22	26,731	4,013	7,104	4,691
31 Dec 21	24,696	3,316	6,784	4,627
30 Sep 21	26,359	3,567	7,436	4,640
30 Jun 21	28,378	3,934	8,285	4,566
31 Mar 21	30,164	4,983	9,176	4,622
31 Dec 20	24,354	4,873	7,041	4,397
30 Sep 20	34,259	6,371	10,719	4,537
30 Jun 20	34,998	6,679	11,085	4,648
31 Mar 20	35,183	5,380	10,993	4,519
31 Dec 19	33,754	4,645	10,962	4,405
30 Sep 19	33,052	4,561	10,103	4,266
30 Jun 19	31,759	4,427	9,575	4,065
31 Mar 19	31,260	3,904	9,488	3,887
31 Dec 18	30,821	3,623	9,500	3,799
30 Sep 18	30,263	1,862	9,234	3,755
30 Jun 18	30,014	1,656	9,185	3,696
31 Mar 18	30,024	1,035	9,143	3,890
31 Dec 17	30,186	1,532	9,424	3,925
30 Sep 17	30,133	2,335	9,303	3,886
30 Jun 17	29,832	1,931	9,260	3,863
31 Mar 17	29,044	1,676	9,017	3,604
31 Dec 16	27,889	912	8,852	3,550
30 Sep 16	26,589	301	8,553	3,370
30 Jun 16	25,174	31	8,025	3,226
31 Mar 16	24,530	615	8,097	3,163
31 Dec 15	23,923	8,422	9,232	3,560
30 Sep 15	23,823	9,809	7,810	3,218
30 Jun 15	23,342	9,672	7,425	3,227

Kaliteli Kazançlar: GLAX.F yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: GLAX.F 'nin mevcut net kar marjları (17.5%) geçen yılın (8.2%) sinden daha yüksektir.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: GLAX.F şirketinin kazancı son 5 yılda yılda 0.3% oranında arttı.

Büyüme Hızlandırma: GLAX.F 'un son bir yıldaki kazanç büyümesi ( 122% ) 5 yıllık ortalamasını (yıllık 0.3% ) aşıyor.

Kazançlar vs. Sektör: GLAX.F geçen yılki kazanç büyümesi ( 122% ) Pharmaceuticals sektörünün 6.6% değerini aştı.

Özkaynak Getirisi

Yüksek ROE: GLAX.F 'nin Özsermaye Getirisi ( 39.41% ) yüksek olsa da, bu ölçüm yüksek borç seviyeleri nedeniyle çarpıktır.

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/04/12 03:18
Gün Sonu Hisse Fiyatı	2026/04/10 00:00
Kazançlar	2025/12/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

GSK plc 46 Bu analistlerden 19, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
John Eade	Argus Research Company
Odile Rundquist	Baader Helvea Equity Research
James Gordon	Barclays

GSK Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 5/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

GSK plc to Report Q4, 2025 Results on Feb 04, 2026

GSK plc to Report Q3, 2025 Results on Oct 29, 2025

GSK plc to Report Q1, 2025 Results on Apr 30, 2025

GSK plc to Report Q4, 2024 Results on Feb 05, 2025

Recent updates

GSK plc Announces Exdensur Approval for CRSwNP in China

Samsung Biologics America, Inc completed the acquisition of Human Genome Sciences Inc. from GSK plc (LSE:GSK).

Bepirovirsen Accepted for Regulatory Review in China as A Potential First-In-Class Functional Cure for Chronic Hepatitis B

GSK PLC Bepirovirsen Accepted For Review By The European Medicines Agency As A Potential First-In-Class Treatment For Chronic Hepatitis B

GSK plc, Annual General Meeting, May 06, 2026

US Food and Drug Administration Approves GSK plc's Lynavoy(linerixibat)

GSK plc Announces Expansion of AREXVY Approval to Adults Aged 18 to 49 Years for RSV Prevention

Angeion Group Announces Proposed Settlement in DeCostanzo v. GlaxoSmithKline

GSK plc Appoints Elizabeth McKee Anderson as Member of the Corporate Responsibility Committee, Effective March 9, 2026

GSK plc (LSE:GSK) completed the acquisition of 93.4% stake in RAPT Therapeutics, Inc. (NasdaqGM:RAPT) for $1.7 billion.

GSK plc Announces That Japan's Ministry of Health, Labour and Welfare Accepts for Review A New Drug Application for Bepirovirsen

GSK plc (LSE:GSK) entered an agreement to acquire 35Pharma Inc for CAD 950 million.

GSK plc Announces New Effectiveness Data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) At RSVVW'26

GSK plc's RSV Vaccine Accepts for Review by China's Center for Drug Evaluation for the Prevention of Lower Respiratory Syncytial Virus Disease

GSK plc Announces Nucala (Mepolizumab) Approval by European Commission for Treatment of Chronic Obstructive Pulmonary Disease (COPD)

Gsk Plc's Rsv Vaccine Receives European Approval for Expanded Use in All Adults 18 Years and Older

GSK plc (LSE:GSK) entered a definitive agreement to acquire RAPT Therapeutics, Inc. (NasdaqGM:RAPT) for $1.7 billion.

GSK plc to Report Q4, 2025 Results on Feb 04, 2026

GSK plc Appoints Luke Victor Miels as Director, Effective January 1, 2026

GSK plc Announces Positive Topline Results from B-Well 1 and B-Well 2 Phase 3 Studies for Bepirovirsen

GSK plc Announces the Approval of Exdensur ( Depemokimab) by Japan's Ministry of Health, Labour and Welfare

GSK plc Announces China's National Medical Products Administration Approval of Nucala (Mepolizumab) as Add-On Maintenance Treatment of Adult Patients with Inadequately Controlled COPD

Samsung Biologics America, Inc. entered into a definitive agreement to acquire Human Genome Sciences Inc. from GSK plc (LSE:GSK) for $280 million.

Spero Therapeutics, Inc. Announces Nda Resubmission of Tebipenem Hbr by Gsk to the Fda for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis

GSK plc Announces Exdensur (depemokimab) Approved by US FDA for the Treatment of Severe Asthma

GSK plc Announces the Marketing Authorisation of Exdensur ( Depemokimab) by the UK's Medicines and Healthcare Products Regulatory Agency

GSK plc Announces US FDA Approval Of Blujepa For Gonorrhoea Indication

GSK plc Receives Orphan Drug Designation from US Food and Drug Administration for the Treatment of Small-Cell Lung Cancer

GSK plc Upgrades Earnings Guidance for the Year Ending December 31, 2025

GSK plc Announces US FDA Approves Blenrep (Belantamab Mafodotin-Blmf) in Combination with Bortezomib and Dexamethasone (BVd) for Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma

GSK plc Announces Positive Phase III Data for Next-Generation Low Carbon Version of Ventolin Metered Dose Inhaler

GSK's Shingrix New Prefilled Syringe Presentation Receives Positive CHMP Opinion

GSK's Shingrix Approved in China for Prevention of Shingles in Adults Aged 18 and over Who are at Increased Risk Due to Immunodeficiency or Immunosuppression

GSK plc to Report Q3, 2025 Results on Oct 29, 2025

GSK plc Announces Major Update to Vaccine Track

US Food and Drug Administration Accepts GSK plc's Gepotidacin as an Oral Option for the Treatment of Unplicated Urogenital Grogenital Grogenital Gonorrhoea

GSK plc Provides Update on US Settlement of CureVac/BioNTech mRNA Patent litigation

GSK plc Declares Second Interim Dividend for Second Quarter of 2025, Payable on 9 October 2025

GSK plc Announces Blenrep (Belantamab Mafodotin) Combinations Approved in EU for Treatment of Relapsed/Refractory Multiple Myeloma

GSK plc Provides Update on US FDA Advisory Committee Review of Blenrep (belantamab Mafodotin-blmf) Combinations

US FDA Accepts Application to Review Expanded Use of GSK's RSV Vaccine, Arexvy, for Adults 18-49 At Increased Risk

GSK plc (LSE:GSK) completed the acquisition of Efimosfermin alfa drug from Boston Pharmaceuticals Inc.

GSK plc Announces FDA Approves Benlysta (belimumab) Autoinjector for Children with Active Lupus Nephritis

Gsk plc Announces Japan's Ministry of Health, Labour and Welfare Accepts Regulatory Application to Expand Use of Gsk's Rsv Vaccine

GSK plc Announces the Linked by Lupus: Optimal Care Initiative to Help Support Individuals with Lupus in the US

GSK plc's RSV Vaccine Accepts for Regulatory Review by the European Medicines Agency to Expand Use in Adults 18 Years and Older

GSK plc announces the US Food and Drug Administration has accepted for review the NDA for linerixibat

GSK plc and Spero Therapeutics Announces PIVOT-PO Phase III Study for Tebipenem HBr Starts Early for Efficacy

GSK plc Announces Blenrep (Belantamab Mafodotin) Combination Receive Positive CHMP Opinion in Relapsed/Refractory Multiple Myeloma

GSK plc Announces Approval Ofenrep Combinations by Japan's Ministry of Health, Labour and Welfare for the Treatment of Adults with Relapsed/Refractory Multiple Myeloma

GSK plc (LSE:GSK) agreed to acquire Efimosfermin alfa drug from Boston Pharmaceuticals Inc. for $2 billion.

GSK plc Announces Positive Results for Nucala

GSK plc Announces the Authorisation of Blenrep by the Medicines and Healthcare Products Regulatory Agency

GSK plc Recommends the Use of RSV Vaccines Including GSK'sAREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted)

GSK plc to Report Q1, 2025 Results on Apr 30, 2025

GSK's Omjjara (Momelotinib) Approves in Singapore as the First Treatment Indicated for Myelofibrosis Patients with Anaemia

GSK plc, Annual General Meeting, May 07, 2025

US Food and Drug Administration Accepts Depemokimab Application for the Use of D Epemokimab in Two Indications

GSK plc (LSE:GSK) announces an Equity Buyback for £2,000 million worth of its shares.

GSK plc (LSE:GSK) completed the acquisition of IDRX, Inc. from a group of shareholders.

GSK plc Announces That The Chinanational Medical Products Administration Has Accepted for Review the New Drug Application for the Use of Nucala (Mepolizumab)

GSK plc Announces Board and Committee Changes

Gsk plc Announces Approval of Penmenvy, Gsk’S 5-In-1 Meningococcal Vaccine by US FDA

GSK plc Provides Earnings Guidance for the Full-Year of 2025; Provides Earning Guidance for 2026

Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against GSK plc

GSK plc Announces Acceptancy of Depemokimab Applications for Review in China and Japan for Asthma with Type 2 Inflammation and CRSwNP

Gsk plc Announces the European Medicines Agency Accepts for Review the Regulatory Application of A Prefilled Syringe Presentation of Shingrix

GSK plc Announces the European Commission Approval to Expand the Use of Jemperli Plus Chemotherapy (Caroplatin and Paclitaxel) for First-Line Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Cancer

GSK plc to Report Q4, 2024 Results on Feb 05, 2025

GSK plc (LSE:GSK) entered into an agreement to acquire IDRX, Inc. from a group of shareholders for approximately $1.2 billion.

Us Food and Drug Administration Accepts GSK Plc's Shingrix New Prefilled Syringe Presentation of Shingrix for the Prevention of Shingles (Herpes Zoster)